LabCompass

Harikrishna Nakshatri

Medicine · Indiana University

OpenAlex ORCID
Established · publishing since 1988Rising activity
Cancer Cells and MetastasisCancer Genomics and DiagnosticsBRCA gene mutations in cancerEstrogen and related hormone effectsGene expression and cancer classification

Publications

716

Citations

18,006

Est. group size

~2

Recurring co-author estimate

Active years

39

Publishing since 1988

Research summary
AI-generated

Harikrishna Nakshatri studies breast cancer at the molecular and cellular level, investigating how genes, hormones, and cell states drive tumor development and resistance to treatment. A major focus is understanding why some breast cancers respond to targeted drugs (such as CDK4/6 inhibitors) while others resist them, as well as how factors like genetic ancestry, hormone receptors, and normal breast tissue changes influence cancer risk and progression. The work combines genomic analysis, single-cell technologies, and studies of healthy and diseased breast tissue.

Breast cancer genomics and biologyHormone receptor signaling (estrogen, androgen, vitamin D)Resistance to targeted cancer therapies (CDK4/6 inhibitors)Ancestry-related differences in breast tissueSingle-cell analysis of breast epithelial and stromal cells

Publication activity has been steady historically with a very large spike in 2023-2024, though counts for the most recent years likely reflect incomplete indexing.

Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026

Funding
Public award records

Current awards run through August 2029 — about 3 years of funding on record from today. Awards are often renewed, so this is what is currently public, not a forecast.

  • ActiveNIH P30CA082709through Aug 2029 · $228k awarded

    Cancer Research Training and Education Coordination

  • ActiveNIH T32CA282070through Aug 2029 · $514k awarded

    Surgical Oncology Research Training at Indiana (SORTI)

  • ActiveNIH U01CA278865through Apr 2029 · $298k awarded

    The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability

  • ActiveNIH R25CA274184through Aug 2028 · $404k awarded

    Educational Pathways for Cancer Research (EPCR)

  • ActiveNIH R25CA269039through Aug 2028 · $285k awarded

    Summer Program for Academic Research in Cancer (SPARC)

11 earlier awards
  • NIH R03CA223906Jan 2018 – Dec 2020 · $79k awarded

    Impact of NF-kB methylation on chemoresistance and metastasis of breast cancer

  • NIH R03CA195250Dec 2015 – Nov 2018 · $78k awarded

    Estrogen-Estrogen Receptor axis in non-transformed breast epithelial cells: studies beyond MCF-7

  • NIH R21CA152536Mar 2011 – Feb 2014 · $167k awarded

    Anthrax Toxin Receptor as a marker and target of breast cancer stem cells

  • NIH R21CA159158Mar 2011 – Feb 2014 · $167k awarded

    Persistent microRNA changes in serum of cancer-free breast cancer patients

  • NIH R03CA143994Sep 2010 – Aug 2013 · $75k awarded

    Chemoprevention of tobacco carcinogen-induced bladder cancer

  • NIH T32CA111198Apr 2005 – Sep 2011 · $322k awarded

    Cancer Biology Training Program

  • NIH R03CA137796Sep 2008 – Feb 2011 · $77k awarded

    Lung Cancer Chemoprevention through LC-1

  • NIH R03CA117486Sep 2007 – Aug 2010 · $76k awarded

    Animal Model for Local Inflammation-Induced Breast Cancer

  • NIH R03CA123561Jul 2006 – Jun 2009 · $74k awarded

    Chemoprevention Through Activation of Estrogen Receptor Alpha-Induced Senescence

  • NIH R01CA089153May 2001 – Apr 2007 · $235k awarded

    AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS

  • NIH R21CA082208May 2000 – Apr 2003 · $112k awarded

    ROLE OF IL-1 ALPHA IN METASTASIS OF BREAST CANCER

Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.

In context
Among 5,073 established Medicine PIs within our index
Citations: 18,006cohort median 2,525
h-index: 69cohort median 24
Publications / year (recent): 79.8cohort median 4.8

Typically publishes in teams of ~7 · 6% small-team papers (≤3 authors) · across 49 venues

Publication cadence
Publications per year over the last 10 years — averaging 79.8/year recently
2017: 23 publications172018: 22 publications182019: 18 publications192020: 25 publications202021: 17 publications212022: 20 publications222023: 247 publications247232024: 97 publications242025: 28 publications252026: 7 publications26
Collaborators per year
Distinct co-authors at Indiana University each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
2017: 16 collaborators at the same institution2018: 0 collaborators at the same institution2019: 0 collaborators at the same institution2020: 9 collaborators at the same institution2021: 1 collaborator at the same institution2022: 0 collaborators at the same institution2023: 2 collaborators at the same institution2024: 7 collaborators at the same institution2025: 0 collaborators at the same institution1719212325
Recent publications
Publishes in
  • Cancer Research×41
  • Figshare×27
  • PMC×15
  • bioRxiv (Cold Spring Harbor Laboratory)×13
  • Clinical Cancer Research×6
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Sep 1, 2026.

Claim or correct this profile